TeicoplaninisaglycopeptideantibioticcomposedofamixtureofrelatedcompoundsusedtotreatinfectionscausedbymethicillinresistantGrampositivebacteria.Teicoplaninissparinglysolubleinwater.
CASNumber
61036-62-2
MolecularFormula
A2-1(CAS91032-34-7)C88H95Cl2N9O33|1877.64|
A2-2(CAS91032-26-7)C88H97Cl2N9O33|1879.65|
A2-3(CAS91032-36-9)C88H97Cl2N9O33|1879.65|
A2-4(CAS91032-37-0)C89H99Cl2N9O33|1893.68|
A2-5(CAS91032-38-1)C89H99Cl2N9O33|1893.68|
A3-1(CAS93616-27-4)C72H68Cl2N8O28|1564.25|
A3-2(CAS91032-39-2)C66H58Cl2N8O23|1402.11|
MolecularWeight
Varies
MechanismofAction
Teicoplaninpreventspeptidoglycansynthesisandpolymerizationbytwoseparatemechanisms.OnemechanismpreventsN-acetylmuramicacid(NAM)andN-acetylglucosamine(NAG)fromlinkingtogetherformingthepeptidoglycanbackbone.Thesecondmechanismpreventscross-linkingbetweenaminoacidresiduesinthepeptidoglycanchain.Thismechanismisnearlyidenticaltovancomycin;however,teicoplaninisconsideredasaferdrugduetoitslowernephrotoxicityandototoxicity.
StorageConditions
2-8°C
TariffCode
2941.90.3000
Spectrum
Teicoplanintargetsprimarilygrampositivebacteriaespeciallythoseresistanttomethicillin.Theseincludethedrugresistantsuperbug,MRSA(MethicillinresistantStaphylococcusaureus)andEnterococcusfaecalis.TeicoplaniniseffectivefortreatingMRSAinfectionsbecauseitinhibitscellwallsynthesisthroughadifferentmechanismthanβ-lactamantibiotics.
Form
Powder
Appearance
Whitetolightyellowpowder
ElementalAnalysis
Composition:
TeicoplaninsA2:≥80.0%
TeicoplaninsA3:≤15.0%
OtherImpurities:≤5.0%
ImpurityProfile
ImpurityA|4-methylpent-3-en-2-one(mesityloxide)|141-79-7|C6H10O|98.14|
pH
6.3-7.7
Assay
(OnDriedBasis):≥900µg/mg